Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
TREACE MEDICAL CONCEPTS, INC. (TMCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Forward Looking Statements and Other Cautions This",
"Treace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries PONTE VEDRA, Fla. – June 1, 2023—Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today announced that it has signed an asset purchase agreement to acquire certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D , a medical technology company offering pre-operative planning and patient-specific guides designed to deliver accurate surgical correction of deformities customized to the patient’s unique foot anatomy, for a purchase price of $20 million in an upfront cash payment, with up to $10 million in potential milestone payments. Using patient CT scan data, RPM-3D applies innovative s..." |
|
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Treace Medical Concepts Reports First Quarter 2023 Financial Results PONTE VEDRA, Fla. – May 8, 2023 — Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today reported financial results for the first quarter ended March 31, 2023. Recent Highlights: • Revenue of $42.2 million in the first quarter of 2023, a 45% increase over the same period last year. • Blended average revenue per Lapiplasty® procedure kit sold was $6,244, a 13% increase over the same period last year and a 6% increase sequentially. • Gross margin of 80.9% in the first quarter 2023. • First quarter revenue contribution from direct sales channel, the industry’s only direct bunion-focused salesforce, increased to 79..." |
|
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/07/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/10/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Treace Medical Concepts Reports Second Quarter 2022 Financial Results PONTE VEDRA, Fla. – August 9, 2022—Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today reported financial results for the second quarter ended June 30, 2022. Recent Highlights: • Revenue of $30.0 million in the second quarter 2022, a 45% increase over the same period last year. Blended average revenue per case increased 5% to over $5,700 from the same period last year. • Gross margin of 81.1% in the second quarter 2022, an increase of 20 basis points from the same period last year. • Second quarter revenue contribution from direct sales channel, the industry’s only direct bunion-focused salesforce, was 68% of sale..." |
|
| 05/23/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob... |
| 03/03/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
8-K
| Quarterly results |
| 01/12/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Treace Medical Concepts Provides 2021 Preliminary Sales Results PONTE VEDRA, Fla. - January 10, 2022—Treace Medical Concepts, Inc. , a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus , today announced preliminary unaudited results for fourth quarter and full year 2021. Preliminary unaudited revenue for the fourth quarter and full year 2021 is anticipated to be in the range of $33.1 to $33.4 million and $94.1 to $94.4 million, respectively, representing an increase in the range of 37% to 39% and 64% to 65% over the same periods last year, respectively. The full year growth rate range benefits from the comparison to the second quarter of 2020, which included Covid related shutdowns. On a sequential basis, the anticipated..." |
|
| 11/04/2021 |
8-K
| Quarterly results |
| 10/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
8-K
| Quarterly results |
| 04/27/2021 |
8-K
| Quarterly results |
|
|